ZEROHour Prostate Cancer Newsletter

ZERO360-With You Every Step of the Way

Navigating prostate cancer goes beyond solely treating the physical symptoms-it's a journey that deeply impacts mental health. Diagnosis can be overwhelming. The unique challenges during phases of treatment can cause a multitude of difficult feelings, especially during the holiday season.

Our flagship program, ZERO360, is a comprehensive support program that offers more than just educational and financial resources. Recognizing the profound importance of taking care of one's mental health, our initiative provides emotional support from diagnosis to survivorship.

Our ZERO360 case managers can connect you with a variety of resources, such as our peer MENtor program and help finding a support group. From connecting with others in the community to fostering meaningful relationships, we aim to alleviate the isolation often felt during treatment. In those early stages, having a peer who understands can make all the difference-providing guidance, reassurance, and a shared understanding of the decisions ahead.

Your mental well-being matters.

Breakthroughs in Prostate Cancer Treatment Research

In a significant development for prostate cancer patients, Pfizer and Astellas announced they received FDA approval for XTANDI to be used for earlier treatment. Healthcare experts, such as Dr. Neal Shore, who has cared for prostate cancer patients for over 40 years, expressed enthusiasm upon hearing this news. Previously, there were limited options for patients who had an increased risk of metastasis.

This groundbreaking approval offers renewed hope to patients, their families, and caregivers.

ZERO's President and CEO, Courtney Bugler, underscored the importance of this research:

"For patients who were previously treated for prostate cancer and had achieved remission, only to later receive the distressing news of disease recurrence with a risk of metastasis, the emotional toll can be profound. This approval of XTANDI is a promising treatment option for the community, offering a ray of hope to patients and their caregivers during these challenging times."

Progress Starts With You

This holiday season, the prostate cancer community is counting on you. Gifts made through December 31 will be DOUBLED to provide the promise of more tomorrows for patients and families that are out of options.

As 2023 comes to a close, families facing the challenges of prostate cancer are hoping for progress now more than ever. Progress is a new and revolutionary treatment option. Progress is more patients spending holidays surrounded by loved ones. Progress is preventing the heartbreak of saying goodbye too soon. Progress is your ZERO community banding together to make a difference.

Don't miss your chance to provide hope for prostate cancer patients and their families and double your 2023 gift today. Every $1 donation becomes $2, helping fund the fight for a world free from prostate cancer. Thank you for ensuring that patients do not face this holiday season alone and for joining us in advancing progress toward a brighter, more hopeful future.

Join ZERO at the UC San Diego Prostate Cancer 101 Community Workshop

Although any man can be diagnosed with prostate cancer, the unfortunate reality is that men with certain risk factors can be disproportionately affected, impacting their access to equitable healthcare. As part of our mission, ZERO aims to address these disparities.

ZERO is proud to be a part of the UC San Diego Prostate Cancer 101 Community Workshop taking place on December 7 from 5:30 - 6:30 p.m. If you're in San Diego, join us for this in person learning opportunity. This event includes comprehensive education about prostate cancer, an expert Q&A session, and informative materials to take home for continuing education. Topics will cover prostate health, early detection, and accessing resources.

Join Kris Bennett, ZERO's Director of Health Equity, as he shares valuable insights about how we can work towards healthcare equality. This workshop is more than just an event; it's an opportunity to empower yourself and become an advocate for prostate health in your community. Let's bridge the gap in understanding and ensure every man has equal access to life-saving treatment.

Simplify Prostate Cancer Care with ZERO's Healthcare Provider Resources

In the fast paced world of healthcare, providers have limited time. ZERO makes it easier than ever to stay up to date on the latest advancements in prostate cancer treatment with our streamlined resources. Our new collaborative provider treatment decision tool, developed with Clinical Care Options, allows you to enter patient characteristics and view the recommendations of five prostate cancer experts. Offer your patients curated resources from ZERO, including support groups, videos, and more, as well as order informative literature for your office.

ZERO takes pride in partnering with accredited continuing education providers, ensuring you stay current with treatment guidelines and advances. Let us help you make your approach to prostate cancer management easier—because when providers are equipped, patients receive the comprehensive care they deserve.

Holiday Giving Tax Smart Giving Options Our work to ZERO out prostate cancer isn't possible without the support of committed community members like you. As the end of the 2023 tax year approaches, many donors ask us about giving options and ways to contribute to ZERO's mission to end prostate cancer. For a comprehensive list of options, visit our website. » Support Patients and Families this holiday season

Summit 2024 End the Year with a Commitment to Summit 2024 ZERO's biggest in person advocacy event of the year will be here before you know it. Sign up for Summit 2024 in Washington, D.C. taking place on February 25 - 27. We will offer valuable insight into furthering your advocacy efforts and advancing our mission to end prostate cancer as a community. » Register for Summit 2024

Blue Earth Webinar On Demand: PSMA PET Webinar ZERO's Vice President of Patient Programs & Education, Shelby Moneer, moderated a Facebook Live discussion with Dr. Alain Chaglassian, a Medical Director from Blue Earth Diagnostics. Blue Earth has recently received FDA approval on POSLUMA, a diagnostic imaging agent for PET imaging for use in patients with suspected metastasis or suspected recurrence of prostate cancer. Discover more on our YouTube channel to access this informative video and determine if POSLUMA is right for you. » Watch the PSMA Pet Webinar (This content is provided in partnership with Blue Earth Diagnostics)

Clinical Study Francis Medical Enrolling for Clinical Study Are you or a loved one battling prostate cancer? The Francis Medical Clinical Study is now enrolling for an investigational treatment for intermediate-risk prostate cancer. Men who are 50+ with biopsy-confirmed prostate cancer might qualify for this new clinical study. » Learn More (This content is provided in partnership with Francis Medical)

Support for this newsletter provided by Janssen Oncology